



Corporate Effectiveness

Addressing ESG & Long-term Sustainability

April 2026

Forward Looking Statements

This presentation contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this presentation include statements regarding the initiation, timing, progress and results of the Company’s preclinical studies and planned clinical trials, including the Company’s expectation to achieve early human proof-of-concept data for EDIT-401 by year-end 2026; and the potential of, and expectations for, EDIT-401 and the Company’s other future *in vivo* product candidates. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation, timing, progress, and results of preclinical studies and clinical trials; uncertainty regarding availability and timing of results from preclinical studies and clinical trials; uncertainties relating to planned regulatory submissions to initiate clinical trials, including that results of preclinical studies will warrant such submissions or that regulatory agencies may require additional preclinical studies, that regulatory submissions shall occur on the expected timelines and that regulatory authorities will provide clearance for trials to be initiated; and that the Company will not be able to raise funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this presentation represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.

All information in this presentation is provided as of April 17, 2026, unless otherwise specified.

A MESSAGE FROM **Gilmore O'Neill** PRESIDENT & CEO

At Editas Medicine, our mission has always been to harness the power and potential of CRISPR gene editing to develop transformative medicines for people living with serious diseases. More than a decade after the discovery of this groundbreaking technology, we are increasingly seeing the potential of gene editing translate into meaningful scientific and clinical progress and outcomes for patients.

In 2025, we took an important step forward in our strategy to be a leader in transformative *in vivo* gene editing with the introduction of our lead development candidate, EDIT-401. This experimental, potential best-in-class, one-time *in vivo* CRISPR gene editing medicine is designed to significantly reduce LDL cholesterol (LDL-C) levels and has the potential to transform the treatment paradigm for hyperlipidemia. In preclinical studies, EDIT-401 demonstrated significantly reduced mean LDL-C levels of over 90 percent – far exceeding the reductions typically achieved by current therapies. If successful in clinical development, EDIT-401 could offer patients an economical, one-time treatment that delivers durable, lifelong reductions in cardiovascular risk.

Cardiovascular disease remains the leading cause of death worldwide, and elevated LDL-C, or hyperlipidemia, is a high prevalent disease affecting over 70 million patients in the United States alone. The promise of EDIT-401 illustrates the broader potential of gene editing: the opportunity to address common and serious diseases in ways that were not previously possible. We are now advancing EDIT-401 toward the clinic, with the goal of generating early human proof-of-concept data by the end of 2026.



While EDIT-401 represents our lead clinical priority, we remain encouraged by progress across our broader pipeline. Our teams continue advancing programs in hematopoietic stem cells while also building the scientific foundation for a broader *in vivo* gene editing portfolio.

This progress reflects our broader vision for Editas: to be a leader in *in vivo* gene editing, and our commitment to improving the lives of those impacted by serious diseases is our core focus. By combining our expertise in CRISPR gene editing with our differentiated upregulation strategy, we are working to develop medicines that have the potential to be first- or best-in-class therapies across a range of serious diseases.

Our progress is made possible by the dedication and expertise of our employees. Across research, development, and operations, the Editas team is united by a shared commitment to advancing our science and our mission. We strive to maintain a culture grounded in collaboration, integrity, and inclusion, where diverse perspectives strengthen innovation and help ensure we remain focused on the long-term impact of our work.

Strong governance and responsible corporate stewardship remain central to how we operate as a company. Our leadership team and Board of Directors are committed to transparency, ethical conduct, and long-term value creation as we continue advancing our pipeline and expanding the potential of gene editing medicine.

On behalf of the entire Editas team, thank you for your continued interest and support. We look forward to sharing further updates as we advance EDIT-401 toward the clinic and continue working to deliver transformative gene editing medicines.

A portrait of Gilmore O'Neill, the President & CEO of Editas Medicine. He is a middle-aged man with short, light-colored hair, wearing a dark suit jacket over a blue collared shirt. He is smiling slightly and looking directly at the camera. The background is a blurred office setting with a large "Editas MEDICINE" logo visible on a wall behind him.

“...we are working to develop medicines that have the potential to be first- or best-in-class therapies across a range of serious diseases.”



*A leader in transformative
in vivo gene editing*



**Differentiated
Upregulation
Strategy**

Novel therapeutic mechanisms
unlocked by functionally upregulating
protein expression



**Delivery to
Target Tissues**

Delivery platform enables precise delivery of
in vivo gene editing medicines across tissue
types (liver and others)



**Transformative
Therapeutic
Potential**

Address **significant unmet needs** via
one-time, durable treatment with meaningful
patient and broader healthcare system impact



EDIT-401: Potential to Transform the Hyperlipidemia Treatment Landscape

A potential best-in-class therapy with **unprecedented >90% mean reduction in LDL-C** in non-human primates¹, **on track to achieve early human proof-of-concept data by end of 2026**

Our Commitment to Patients

ENGAGE REGULARLY

Seek out opportunities to learn from the communities we aim to create a treatment option for and continue to bring their voices into decision making and drug development planning.

LISTEN ACTIVELY

Health and treatment is deeply personal, and there are similarities and differences across diseases, and among individuals affected by the same disease. It is critical that we listen and understand diverse perspectives.

ENGAGE AUTHENTICALLY

We are optimistic about the promise of gene editing, yet there is still much to be learned. Through transparent communication about Editas Medicine and our approach to developing medicines, we hope to ensure the expectations we set are realistic.

Executive Compensation Philosophy

Our goal is to implement an executive compensation program that attracts and retains qualified and talented executives, motivates such executives to achieve our business goals and rewards them for short- and long-term performance with a simple and clear compensation structure.

- Maintain and evaluate annually an industry-specific peer group for benchmarking pay
- Review annually our compensation strategy to ensure target pay is based on market norms
- Balance short- and long-term incentives (through annual cash bonuses and equity awards)
- Maintain a compensation recovery or "clawback" policy
- Use multiple performance measures to determine incentive payouts
- Engage an independent compensation consultant




- No employment agreements that guarantee a certain compensation level or employment term
- No guaranteed annual salary increases or guaranteed bonuses
- No single-trigger vesting in connection with a change-in-control for equity awards
- No excessive executive perquisites or personal benefits
- No hedging or pledging or speculative transaction in our securities
- No re-pricing of equity awards without stockholder approval
- No excise tax gross-ups

Performance Based Executive Compensation Model

- ✓ Incentives linked to actions that create sustainable stockholder value
- ✓ Significant equity focus strengthens alignment of interests with those of long-term stockholders
- ✓ Significant majority of pay is at-risk
- ✓ No guaranteed bonus or awards
- ✓ No guaranteed employment term

2025 Target Executive Compensation



¹ Ms. Parison's initial annual base salary for 2025 was \$340,000 but was increased to \$415,000 in connection with her promotion in March 2025 to Chief Financial Officer. For purposes of this chart, her annual base salary following promotion has been annualized.

Experienced Board of Directors



Jessica Hopfield, Ph.D.

Independent director since 2018

Principal,
J. Hopfield Consulting



Bernadette Connaughton

Independent director since 2021

Former President, Intercontinental,
Bristol Myers Squibb



Andrew Hirsch

Independent director since 2017

President & CEO,
C4 Therapeutics



Elliott Levy, M.D.

Independent director since April 2023

Venture Partner,
5AM Venture Management, LLC



Gilmore O'Neill, M.B., M.M.Sc.

President and CEO,

Editas Medicine











David Scadden, M.D.

Independent director since 2019

Gerald & Darlene Jordan Professor of Medicine
Harvard University

Female Board Chair and 2 of 3 Board Committees Chaired by Female Directors

NAME & AGE	OTHER PUBLIC DIRECTORSHIPS	EDITAS COMMITTEES		
		A	NCG	OLC
Bernadette Connaughton, 67	Halozyme Therapeutics (HALO)			
Andrew Hirsch, 55	C4 Therapeutics (CCCC)			
Jessica Hopfield, 61 Chair	Insulet Corporation (PODD)			
Elliot Levy, 67	NuCana plc (NCNA)			
David Scadden, 73	Agios Pharmaceuticals (AGIO)			
Gilmore O'Neill, 61	None			

A=Audit Committee
NCG=Nominating and Corporate Governance Committee
OLC=Organization, Leadership and Compensation Committee

 MEMBER  CHAIR

64
YEARS
AVERAGE AGE OF
BOARD MEMBER

6
YEARS
AVERAGE TENURE
ON EDITAS' BOARD

33%
WOMEN

Experienced Team Focused on Delivering Shareholder Value



Gilmore O'Neill, M.B, M.M.Sc.
Chief Executive Officer
Prior experience: Sarepta • Biogen



Briana Buckley, PharmD, MS
SVP, Development and Program Leader
Prior experience: Rhythm • Biogen • Bioverativ • Sanofi



Linda Burkly, Ph.D.
Chief Scientific Officer
Prior experience: Biogen • Lightstone Ventures • Exo Therapeutics



Damien Grierson
SVP, General Counsel
Prior experience: American Renal Associates • K&L Gates • Cooley • A&O Sherman



Frank Panaccio
Chief Business Officer
Prior experience: Parexel • Lumanity • Fidelity • Jefferies



Amy Parison
Chief Financial Officer
Prior experience: Rubius Therapeutics • Vertex • PWC



Gregory Whitehead
Chief Technical and Quality Officer
Prior experience: Rubius Therapeutics • bluebird bio • Dendreon




Tom Love
VP, People
Prior experience: Kymera • forma Therapeutics • Randstad Sourcright

Corporate Governance Highlights

Our governance structure strives to ensure independent oversight of an experienced management team and protection of long-term stockholder value

- Board-level oversight of material enterprise risks
- Management gives periodic reports to the Board or its Committees on cybersecurity risks
- Clawback policy and clawback provisions in equity awards
- Prohibition on hedging and pledging shares of company stock by executive officers and directors
- Commitment to Board refreshment, with a robust director nominee selection process
- Mandatory retirement age of 75
- Codified commitment to include a diverse range of qualified professions for nominee selection



- Supermajority of independent directors
- Separate Board Chair and CEO roles
- 100% independent Board committees
- Regular executive sessions of independent directors
- Annual Board and committee evaluations
- Overboarding limits for directors
- Annual “say-on-pay” vote
- One single voting class of stock
- Proactive annual stockholder engagement program
- No “poison pill”

Focusing on the Environment



GREEN FACILITIES

- Electrical systems designed for optimal performance and sustainability.
- Low-emitting, partially recycled materials installed throughout facilities.
- Use of energy saving equipment; automatic lighting shutoff controls to help lower energy usage.
- Daylight and motion sensors allow full spectrum of natural light; LED fixtures used only when necessary.



ENERGY & WATER CONSERVATION

- High efficiency water fixtures.
- High efficiency mechanical and laboratory equipment.
- High efficiency windows reduce solar heat gain.
- Energy efficient hot water boilers.
- State of the art wastewater control system.
- Effluent is monitored and treated with acid or base prior to release.
- Sink wastewater recycled back to washrooms.



WASTE MANAGEMENT

- Responsible biowaste and chemical waste disposal.
- Lab sustainability initiatives for recycling lab consumable plasticware.
- All lab sink waste goes directly to separated storage tanks for specialized disposal.
- Recycle batteries through third party vendor.

Human Capital Management

Our success is based on good science, and good science is based on good people working in a safe and collaborative environment

Editas employees, or Editors, are the fuel that drives our progress. Facilitating a culture that gives each Editor an opportunity to succeed is inherently based on important values that we strive to promote, as well as our ability to attract, retain, develop and motivate new talent. To do this, Editas offers employment packages, resources, and tools to foster a diverse and motivated workforce.

- ✔ Employment salary and bonus packages promoting well-being, including healthcare, retirement planning and flexible time off.
- ✔ Opportunities for equity ownership, including stock-based compensation awards and an employee stock purchase plan.
- ✔ Work/Life balance arrangements including core hours and flexible work arrangements.
- ✔ Regular benchmarking against industry peers to ensure Editas remains competitive and attractive to potential new hires.
- ✔ Development programs enabling continued learning and professional growth, including peer mentorship programs and access to LinkedIn Learning classes.
- ✔ Individual goal setting process, including regular conversations between employees and managers, promoting individual development and career growth.

Editas Culture

The Editas Culture Committee is an employee-led group that works to ensure our day-to-day culture reflects our company values through learning opportunities, community, teambuilding events and forums for all editors.

We work together with integrity and joy, under the framework of our collective goal to develop transformative medicines for people living with serious diseases around the world.

The program brings people together through diverse forums and events, including:

- Philanthropic activities to support our local community, such as toy and clothing drives and patient advocacy support through participation in community events in our therapeutic areas of focus.
- Employee focused initiatives to improve engagement and recognition and to foster a culture of continuous learning and development.
- Social events and celebrations including Lunar New Year, Olympics and World Cup celebrations, and other events throughout the year.
- Corporate sponsorship and employee participation in the Prouty charity bike ride and JP Morgan Corporate Challenge.
- Green initiatives focused on improving sustainability and reducing waste.

PILLARS of EDITAS CULTURE





Representative Differences

Editas routinely reviews representational data and identifies a diverse pool of candidates for all job openings to ensure we remain an inclusive culture that continues to strengthen through diversity



Senior Management

All Editas Medicine Employees

Gender Diversity



Ethnic/Racial Diversity



Strong Cybersecurity Protecting IP, Research, Data, and Operations



PROTECTING SCIENTIFIC INNOVATION

- Strong identity security including single sign-on, multi-factor authentication, and controlled privileged access to corporate and research systems.
- Advanced endpoint protection and detection securing systems accessing company data.
- Expanded vulnerability management resulting in an 83% reduction in high-risk vulnerabilities.
- Encryption protecting sensitive data in transit and at rest.



CYBER RESILIENCE & THREAT DEFENSE

- 24/7 threat monitoring through a managed Security Operations Center.
- 24/7 security operations response for rapid incident investigation and remediation.
- Formal Incident Response program with defined escalation procedures and coordination with executive leadership and external partners.
- Enhanced security awareness program with 31% reduction in phishing clicks and 81% increase in reporting.



GOVERNANCE, RISK, & COMPLIANCE

- Comprehensive cybersecurity program led by an experienced Chief Information Security Officer with deep biotechnology industry experience and expertise.
- Risk-based cybersecurity program aligned with the NIST Cybersecurity Framework.
- Annual independent penetration testing to identify and remediate security weaknesses.
- Governance framework for responsible AI use, including policy, oversight committee, and application review process.

Employee Safety is our First Priority

Our safety objective is to facilitate a safe work environment for employees, contractors and third-parties

TRAINING

- ✓ Mandatory safety training for every employee
- ✓ Mandatory annual lab safety training for lab employees
- ✓ Optional training for CPR/AED
- ✓ Employees working in the BL2 lab are required to wear a lab coat, safety glasses and gloves at all times
- ✓ Semi-annual evacuation drills



SAFETY PRECAUTIONS

- ✓ Fire extinguishers, emergency showers, eye wash stations, spill kits, first aid kits and AED machines throughout the buildings and laboratories
- ✓ All biosafety cabinets and fume hoods are certified annually
- ✓ Employees are offered free of charge Hepatitis B three shot series, titer, and booster. Additionally, we have annually on-site Flu Vaccine Clinic, where employees are offered free of charge flu shots.
- ✓ Safety glasses clinics are held quarterly, free of charge to full-time employees to get prescription and non-prescription safety glasses